Related Experiment Video

Updated: Jul 14, 2026

Rat Mesentery Angiogenesis Assay
18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Antiangiogenesis, anti-VEGF(R) and outlook

Iver Petersen1

  • 1Institüt für Pathologie, Rudolf-Virchow-Haus, Humboldt-Universität Berlin, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|July 5, 2007
PubMed

Insights

Tumor angiogenesis, the growth of new blood vessels in tumors, is now a key target for cancer therapy. This review covers anti-angiogenesis strategies, focusing on vascular endothelial growth factor (VEGF).

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor angiogenesis is crucial for cancer growth and metastasis.
  • Anti-angiogenesis therapies represent a promising targeted cancer treatment strategy.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis.

Purpose of the Study:

  • To provide a comprehensive review of tumor angiogenesis and anti-angiogenesis.
  • To summarize the biological activity, gene expression, and regulation of VEGF and its receptors.
  • To overview current clinical trials of angiogenesis inhibitors in oncology.

Main Methods:

  • Literature review focusing on tumor angiogenesis and anti-angiogenesis.
  • Detailed summary of vascular endothelial growth factor (VEGF) biology.
  • Compilation of naturally occurring modulators and clinical trial data for angiogenesis inhibitors.

Main Results:

  • Tumor angiogenesis has transitioned from research to clinical application.
  • VEGF signaling pathways are critical targets for anti-cancer drugs.
  • Numerous angiogenesis inhibitors are under investigation in clinical trials.

Conclusions:

  • Anti-angiogenesis targeting VEGF is a validated and evolving approach in cancer therapy.
  • Understanding VEGF regulation and inhibition is vital for developing effective oncology treatments.
  • The field of angiogenesis inhibition offers a rapidly developing and promising outlook for cancer patients.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...